Mara Goldstein
Stock Analyst at Mizuho
(0.67)
# 2220
Out of 5,326 analysts
90
Total ratings
28.00%
Success rate
-0.23%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
VSTM Verastem | Maintains: Outperform | 9 8 | 7.51 | 6.52% | 7 | Apr 9, 2025 | |
KURA Kura Oncology | Maintains: Strong Buy | 26 32 | 6.42 | 398.44% | 2 | Jan 31, 2024 | |
RCUS Arcus Biosciences | Maintains: Buy | 51 42 | 8.42 | 398.81% | 4 | Jan 30, 2024 | |
XNCR Xencor | Maintains: Buy | 59 50 | 10.85 | 360.83% | 2 | Jan 22, 2024 | |
SNDX Syndax Pharmaceutica... | Initiates Coverage On: Buy | 45 | 13.3 | 238.35% | 1 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 82 77 | 58.99 | 30.53% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 8 7 | 1.39 | 403.6% | 3 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 8 | 1.35 | 492.59% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 20 12 | 0.39 | 2976.92% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 30 | 3.34 | 798.2% | 4 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 6 | 0.73 | 721.92% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 4 | 3.67 | -4.63% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 40 30 | n/a | n/a | 3 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 0.18 | 6566.67% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 10 20 | 1.47 | 1260.54% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 130 | 79.95 | 62.6% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 2 | 0.77 | 159.74% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 2 | n/a | n/a | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 12 | 1.39 | 763.31% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 9 | 0.27 | 3233.33% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 500 | n/a | n/a | 1 | Oct 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 13 10 | n/a | n/a | 2 | Sep 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 96 | n/a | n/a | 4 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 14 20 | 40.35 | -50.43% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 48 | 4.57 | 950.33% | 4 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 135 45 | 19.62 | 129.36% | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22800 6000 | n/a | n/a | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 14 | 5.03 | 178.33% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 9 | n/a | n/a | 1 | Sep 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 15 | n/a | n/a | 1 | Jul 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 6 | n/a | n/a | 2 | Apr 18, 2017 |